ClinicalTrials.gg
TerminatedNCT06237309NATRIX-BNPUpdated Nov 19, 2026Results posted

REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction

A Phase 2 interventional study of REGN5381 and Placebo in Heart Failure, sponsored by Regeneron Pharmaceuticals. Terminated at 44 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Sponsor decision
Updated Nov 19, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
89
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 197 studies in Heart Failure with a site in Belgium — 27 open to participants now, 45 under way, 8 of them phase 3. Heart Failure · Belgium.

Enrollment
105th of 155
89 · median 262
Started
2024
with 11 others
Phase 2
23 of 197
none open now
Registered
176th of 197
by date

Among the 197 studies in Heart Failure with a site in Belgium, this one is the 105th largest by enrollment of the 155 interventional ones that give a count, is one of 12 that started in 2024, is one of 23 in phase 2, and was the 176th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

27 of the 197 studies in Heart Failure with a site in Belgium are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 197 studies in Heart Failure with a site in Belgium, or all of them as a file.
02

Study summary

This study is researching an experimental drug called REGN5381 (called "study drug"). The study is focused on patients with heart failure with reduced ejection fraction (ie, the heart is not functioning as well as it should).

The aim of the study is to see how safe, tolerable, and effective the study drug is.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drug
  • How much study drug is in the blood at different times
  • Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Read the detailed description

Enrollment for the Part A2 low eGFR cohort has been closed

03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • Heart failure with reduced ejection fraction (HFrEF)
  • Reduced ejection fraction
  • N-terminal pro-brain natriuretic peptide (NT-proBNP) hormone
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  1. (BMI) between 18 and 45 kg/m\^2, inclusive, at initial screening visit
  2. Diagnosis of chronic heart failure
  3. 20-49% by echocardiogram performed within 3 months of screening
  4. Plasma NT-proBNP ≥800 pg/mL (or ≥1000 pg/mL if in atrial fibrillation) at screening (visit 1) and NT-proBNP ≥600 pg/mL (or ≥800 pg/mL if in atrial fibrillation) approximately 30 days prior to randomization (visit 5)
  5. Receiving optimized standard of care therapy for heart failure as described in the protocol
  6. Sacubitril-valsartan treatment:

    a. Treatment with sacubitril-valsartan at screening and at baseline permitted in Part A2 sacubitril-valsartan cohort and in Part B if supported by safety data from the Part A2 sacubitril-valsartan cohort as described in the protocol

  7. Estimated (eGFR) levels:

    1. eGFR of ≥30 mL/min/1.73 m2 according to locally used formula (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] preferred), at screening (visit 1) or approximately 30 days prior to randomization (visit 5) as described in the protocol

Key Exclusion Criteria

  1. Hospital discharge within 180 days of anticipated randomization
  2. Resting SBP that remains out of range after two repeated measurements prior to randomization as described in the protocol
  3. Current or recent diagnosis of acute coronary syndrome or myocardial infarction as described in the protocol
  4. History of symptomatic autonomic dysfunction as evidenced by orthostatic hypotension and/or syncope
  5. Unexplained syncope \<12 months prior to initial screening or during the Run-in period
  6. History of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric, or neurological disease, as assessed by the investigator that may confer unreasonable risk to the participant's participation in the study
  7. Uncorrected congenital heart disease
  8. Cardiac surgery within 6 months prior to screening or any planned surgery during the study
  9. Implantation of a cardiac resynchronization therapy device in the prior 90 days, or planned during the study, or planned device optimization 30 days prior to randomization or during the study
  10. Current chronic lung disease requiring long-term oxygen therapy

Note: Other protocol-defined inclusion/ exclusion criteria apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
89 participants (actual)

Study arms

  • Experimental
    Part A1 High Dose

    Single ascending dose cohort

    Drug: REGN5381

  • Experimental
    Part A1 Low Dose

    Single ascending dose cohort

    Drug: REGN5381

  • Experimental
    Part A1 Optional

    Single ascending dose cohort

    Drug: REGN5381

  • Experimental
    Part A2 High Dose, sacubitril-valsartan group

    Single ascending dose cohort

    Drug: REGN5381

  • Experimental
    Part A2 Low Dose, sacubitril-valsartan group

    Single ascending dose cohort

    Drug: REGN5381

  • Placebo comparator
    Placebo for Part A2, sacubitril-valsartan group

    Drug: Placebo

  • Experimental
    Part A2 High Dose, Low estimated glomerular filtration rate (eGFR) group

    Single ascending dose cohort. Note: This group has been closed

    Drug: REGN5381

  • Experimental
    Part A2 Low Dose, Low eGFR group

    Single ascending dose cohort. Note: This group has been closed

    Drug: REGN5381

  • Placebo comparator
    Placebo for Part A2, Low eGFR group

    Note: This group has been closed

    Drug: Placebo

  • Experimental
    Part B High Dose

    Drug: REGN5381

  • Experimental
    Part B Low Dose

    Drug: REGN5381

  • Placebo comparator
    Part A1 and Part B Placebo Only

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Fold Change From Baseline in Circulating N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP)

    NT-proBNP is a clinical biomarker of heart failure. Coefficient of Variation for Fold Change from Baseline was computed as (standard deviation of the natural log-scale of the respective variable) \*100. Fold Change from Baseline is the ratio of Post-baseline to Baseline, and it is assumed to follow a lognormal distribution.

    Time frame: Baseline, Day 8

Secondary outcomes

  1. Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE) by Severity

    TEAEs are defined as those adverse events (AEs) with either initial onset after the first dose of study treatment or that worsen after the first dose of study treatment. The severity of an AE was graded according to the following scale: * Mild: Does not interfere in a significant manner with the participant's normal functioning level. * Moderate: Produces some impairment of functioning but is not hazardous to health. * Severe: Produces significant impairment of functioning or incapacitation and is a definite hazard to the participant's health. A summary of other non-serious AEs and all serious AEs, regardless of causality, is located in the Reported AE section.

    Time frame: Up to Week 16

  2. Fold Change From Baseline in Circulating NT-proBNP

    NT-proBNP is a clinical biomarker of heart failure. Coefficient of Variation for Fold Change from Baseline was computed as (standard deviation of the natural log-scale of the respective variable) \*100. Fold Change from Baseline is the ratio of Post-baseline to Baseline, and it is assumed to follow a lognormal distribution.

    Time frame: Baseline, Days 15, 22, 29, 57, 85, 113

  3. Change From Baseline in Systolic Blood Pressure (SBP)

    Time frame: Day 1 (1,2,4,8hrs post-dose readings), Day 2 (24hrs post-dose readings 1,2,3), Day 3 (48hrs post-dose readings 1,2,3), Day 4 (72hrs post-dose readings 1,2,3), Day 5 (96hrs post-dose readings 1,2,3), Day 8, Day 15, Day 22, Day 29, Day 57, Day 85, Day 113

  4. Change From Baseline in Diastolic Blood Pressure (DBP)

    Time frame: Day 1 (1,2,4,8hrs post-dose readings), Day 2 (24hrs post-dose readings 1,2,3), Day 3 (48hrs post-dose readings 1,2,3), Day 4 (72hrs post-dose readings 1,2,3), Day 5 (96hrs post-dose readings 1,2,3), Day 8, Day 15, Day 22, Day 29, Day 57, Day 85, Day 113

  5. Change From Baseline in Mean Arterial Pressure (MAP)

    Time frame: Day 1 (1,2,4,8hrs post-dose readings), Day 2 (24hrs post-dose readings 1,2,3), Day 3 (48hrs post-dose readings 1,2,3), Day 4 (72hrs post-dose readings 1,2,3), Day 5 (96hrs post-dose readings 1,2,3), Day 8, Day 15, Day 22, Day 29, Day 57, Day 85, Day 113

  6. Change From Baseline in Heart Rate (HR)

    Time frame: Day 1 (1,2,4,8hrs post-dose readings), Day 2 (24hrs post-dose readings 1,2,3), Day 3 (48hrs post-dose readings 1,2,3), Day 4 (72hrs post-dose readings 1,2,3), Day 5 (96hrs post-dose readings 1,2,3), Day 8, Day 15, Day 22, Day 29, Day 57, Day 85, Day 113

  7. Concentration of Total REGN5381 in Serum

    Time frame: Day 0 (pre-dose), Day 0 (post-dose), Days 1, 2, 3, 4, 7, 14, 21, 28, 56, 84, 112

  8. Number of Participants With a Treatment-Emergent Anti-Drug Antibody (ADA) Response to REGN5381

    Time frame: Up to Week 16

  9. Maximum Titer Category of Participants With ADAs to REGN5381

    Time frame: Up to Week 16

07

Results

Posted Nov 19, 2026
Limitations and caveats
This trial was terminated early due to sponsor decision. The decision was not based on any observed safety signal.

Participant flow

Participant flow — Overall Study
MilestonePlacebo: Not on SVPlacebo: on SVREGN5381 100 Milligrams (mg): Not on SVREGN5381 100 mg: On SVREGN5381 300 mg: Not on SV
Started35919917
Received study drug35919917
Not low egfr33917917
Low egfr20200
Completed33919917
Not completed20000
Withdrew: Death10000
Withdrew: Withdrawal by subject10000

Outcome measures

PrimaryFold Change From Baseline in Circulating N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP)

NT-proBNP is a clinical biomarker of heart failure. Coefficient of Variation for Fold Change from Baseline was computed as (standard deviation of the natural log-scale of the respective variable) \*100. Fold Change from Baseline is the ratio of Post-baseline to Baseline, and it is assumed to follow a lognormal distribution.

Time frame:
Baseline, Day 8
Reported as:
Geometric mean · fold change
Fold Change From Baseline in Circulating N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP)
fold changePlacebo: Not on SVPlacebo: on SVREGN5381 100 Milligrams (mg): Not on SVREGN5381 100 mg: On SVREGN5381 300 mg: Not on SV
Fold Change From Baseline in Circulating N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP)0.95 ± 57.11.29 ± 37.10.97 ± 40.31.73 ± 58.21.08 ± 59.8
SecondaryNumber of Participants With at Least One Treatment Emergent Adverse Event (TEAE) by Severity

TEAEs are defined as those adverse events (AEs) with either initial onset after the first dose of study treatment or that worsen after the first dose of study treatment. The severity of an AE was graded according to the following scale: * Mild: Does not interfere in a significant manner with the participant's normal functioning level. * Moderate: Produces some impairment of functioning but is not hazardous to health. * Severe: Produces significant impairment of functioning or incapacitation and is a definite hazard to the participant's health. A summary of other non-serious AEs and all serious AEs, regardless of causality, is located in the Reported AE section.

Time frame:
Up to Week 16
Reported as:
Count of participants · Participants
Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE) by Severity
ParticipantsPlacebo: Not on SV, Not Low eGFRPlacebo: Not on SV, Low eGFRPlacebo: on SVREGN5381 100 Milligrams (mg): Not on SV, Not Low eGFRREGN5381 100 mg: Not on SV, Low eGFRREGN5381 100 mg: On SVREGN5381 300 mg: Not on SV
Participants with at least one Mild TEAE4111032
Participants with at least one Moderate TEAE3001030
Participants with at least one Severe TEAE1011011
SecondaryFold Change From Baseline in Circulating NT-proBNP

NT-proBNP is a clinical biomarker of heart failure. Coefficient of Variation for Fold Change from Baseline was computed as (standard deviation of the natural log-scale of the respective variable) \*100. Fold Change from Baseline is the ratio of Post-baseline to Baseline, and it is assumed to follow a lognormal distribution.

Time frame:
Baseline, Days 15, 22, 29, 57, 85, 113
Reported as:
Geometric mean · fold change
Fold Change From Baseline in Circulating NT-proBNP
fold changePlacebo: Not on SVPlacebo: on SVREGN5381 100 Milligrams (mg): Not on SVREGN5381 100 mg: On SVREGN5381 300 mg: Not on SV
Fold change from baseline to Day 151.13 ± 50.81.19 ± 25.01.15 ± 46.71.71 ± 68.01.26 ± 56.8
Fold change from baseline to Day 221.00 ± 48.71.15 ± 37.21.11 ± 63.21.29 ± 63.00.93 ± 61.8
Fold change from baseline to Day 291.11 ± 52.41.39 ± 65.51.20 ± 47.61.61 ± 62.51.07 ± 88.1
Fold change from baseline to Day 571.07 ± 48.61.41 ± 37.20.84 ± 62.51.04 ± 40.40.96 ± 73.2
Fold change from baseline to Day 851.04 ± 53.61.09 ± 35.40.91 ± 83.80.90 ± 50.30.82 ± 68.5
Fold change from baseline to Day 1131.01 ± 68.71.18 ± 22.10.82 ± 72.71.31 ± 32.90.90 ± 79.7
SecondaryChange From Baseline in Systolic Blood Pressure (SBP)
Time frame:
Day 1 (1,2,4,8hrs post-dose readings), Day 2 (24hrs post-dose readings 1,2,3), Day 3 (48hrs post-dose readings 1,2,3), Day 4 (72hrs post-dose readings 1,2,3), Day 5 (96hrs post-dose readings 1,2,3), Day 8, Day 15, Day 22, Day 29, Day 57, Day 85, Day 113
Reported as:
Mean · millimeters of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure (SBP)
millimeters of mercury (mmHg)Placebo: Not on SVPlacebo: on SVREGN5381 100 Milligrams (mg): Not on SVREGN5381 100 mg: On SVREGN5381 300 mg: Not on SV
Day 1 - 1 hour post-dose reading0.1 ± 12.65-7.7 ± 15.060.5 ± 12.70-10.9 ± 5.40-2.4 ± 7.77
Day 1 - 2 hours post-dose reading-6.6 ± 11.76-9.4 ± 15.13-14.8 ± 12.96-12.8 ± 11.19-11.8 ± 8.65
Day 1 - 4 hours post-dose reading-4.3 ± 13.93-11.0 ± 14.80-13.4 ± 12.94-16.8 ± 15.55-8.8 ± 7.37
Day 1 - 8 hours post-dose reading-6.2 ± 14.64-12.0 ± 9.03-11.6 ± 13.45-3.2 ± 11.73-11.2 ± 10.09
Day 2 - 24 hours post-dose reading 1-3.9 ± 13.21-10.6 ± 10.57-10.2 ± 13.68-6.7 ± 12.97-7.3 ± 11.74
Day 2 - 24 hours post-dose reading 2-6.5 ± 14.49-9.2 ± 9.02-12.1 ± 16.96-14.2 ± 14.59-6.8 ± 12.95
Day 2 - 24 hours post-dose reading 3-2.7 ± 14.30-14.0 ± 6.19-9.8 ± 17.70-5.9 ± 14.62-6.1 ± 12.64
Day 3 - 48 hours post-dose reading 1-3.5 ± 14.61-8.0 ± 11.03-1.3 ± 16.36-3.8 ± 13.56-2.5 ± 14.58
Day 3 - 48 hours post-dose reading 2-2.2 ± 11.79-11.3 ± 9.21-6.2 ± 15.48-4.7 ± 13.96-3.3 ± 12.89
Day 3 - 48 hours post-dose reading 3-4.2 ± 15.01-14.0 ± 5.24-5.4 ± 15.04-4.1 ± 10.120.4 ± 10.86
Day 4 - 72 hours post-dose reading 1-3.8 ± 15.74-4.9 ± 14.23-4.4 ± 15.90-0.8 ± 15.950.6 ± 12.28
Day 4 - 72 hours post-dose reading 2-2.6 ± 16.32-4.3 ± 12.11-1.5 ± 17.72-0.2 ± 22.37-1.8 ± 12.56
Day 4 - 72 hours post-dose reading 3-2.8 ± 13.68-12.4 ± 6.44-8.2 ± 11.520.2 ± 23.52-2.5 ± 8.94
Day 5 - 96 hours post-dose reading 1-1.9 ± 14.74-10.0 ± 5.70-1.5 ± 16.32-4.5 ± 9.29-1.2 ± 11.53
Day 5 - 96 hours post-dose reading 2-1.3 ± 11.27-6.4 ± 15.11-5.5 ± 6.36-10.1 ± 7.43-4.5 ± 3.54
Day 5 - 96 hours post-dose reading 30.7 ± 13.05——-18.0—
Day 8-5.2 ± 12.22-2.4 ± 13.020.8 ± 13.66-6.5 ± 12.50-0.4 ± 11.38
Day 150.0 ± 15.04-11.2 ± 17.344.9 ± 13.641.6 ± 19.203.9 ± 13.28
Day 220.6 ± 13.97-5.6 ± 13.222.6 ± 13.993.3 ± 17.356.6 ± 15.60
Day 29-1.6 ± 15.18-2.9 ± 12.452.2 ± 13.131.7 ± 15.762.6 ± 13.20
Day 571.6 ± 15.33-5.1 ± 14.893.7 ± 11.88-3.0 ± 7.53-0.1 ± 10.80
Day 850.5 ± 14.51-4.7 ± 11.493.6 ± 15.93-5.8 ± 15.181.9 ± 14.18
Day 1130.4 ± 15.70-6.8 ± 13.114.1 ± 19.26-2.6 ± 15.402.4 ± 13.70
SecondaryChange From Baseline in Diastolic Blood Pressure (DBP)
Time frame:
Day 1 (1,2,4,8hrs post-dose readings), Day 2 (24hrs post-dose readings 1,2,3), Day 3 (48hrs post-dose readings 1,2,3), Day 4 (72hrs post-dose readings 1,2,3), Day 5 (96hrs post-dose readings 1,2,3), Day 8, Day 15, Day 22, Day 29, Day 57, Day 85, Day 113
Reported as:
Mean · mmHg
Change From Baseline in Diastolic Blood Pressure (DBP)
mmHgPlacebo: Not on SVPlacebo: on SVREGN5381 100 Milligrams (mg): Not on SVREGN5381 100 mg: On SVREGN5381 300 mg: Not on SV
Day 1 - 1 hour post-dose reading-1.5 ± 9.33-5.4 ± 7.86-1.0 ± 9.02-9.6 ± 8.79-1.0 ± 9.20
Day 1 - 2 hours post-dose reading-6.6 ± 8.12-5.7 ± 9.14-10.0 ± 9.98-8.1 ± 13.05-9.5 ± 9.34
Day 1 - 4 hours post-dose reading-3.9 ± 9.94-2.4 ± 6.88-8.8 ± 11.63-8.1 ± 10.88-7.4 ± 8.65
Day 1 - 8 hours post-dose reading-5.7 ± 8.51-6.1 ± 10.23-7.2 ± 10.74-3.1 ± 8.99-9.1 ± 9.60
Day 2 - 24 hours post-dose reading 1-1.7 ± 8.20-3.4 ± 9.79-7.3 ± 10.940.6 ± 10.96-3.4 ± 8.82
Day 2 - 24 hours post-dose reading 2-4.5 ± 8.84-4.7 ± 8.19-7.6 ± 10.86-8.8 ± 12.26-2.8 ± 11.33
Day 2 - 24 hours post-dose reading 3-3.5 ± 9.77-1.8 ± 6.16-7.9 ± 13.23-7.2 ± 17.31-3.2 ± 13.24
Day 3 - 48 hours post-dose reading 1-3.7 ± 9.87-6.0 ± 2.920.4 ± 10.98-6.6 ± 14.890.1 ± 10.68
Day 3 - 48 hours post-dose reading 2-4.0 ± 9.48-6.4 ± 8.68-5.4 ± 10.74-3.3 ± 9.06-1.6 ± 10.78
Day 3 - 48 hours post-dose reading 3-2.7 ± 10.00-5.4 ± 12.12-4.3 ± 10.15-0.2 ± 11.490.2 ± 10.32
Day 4 - 72 hours post-dose reading 1-2.5 ± 11.78-2.6 ± 11.25-1.4 ± 10.493.6 ± 15.802.8 ± 8.87
Day 4 - 72 hours post-dose reading 2-3.9 ± 11.020.3 ± 10.95-1.9 ± 10.45-0.6 ± 15.05-1.2 ± 12.13
Day 4 - 72 hours post-dose reading 3-3.1 ± 10.25-1.8 ± 9.41-5.5 ± 10.333.0 ± 13.22-1.4 ± 10.08
Day 5 - 96 hours post-dose reading 1-1.7 ± 10.87-2.3 ± 6.871.2 ± 10.011.6 ± 9.832.4 ± 7.59
Day 5 - 96 hours post-dose reading 2-0.3 ± 6.44-1.3 ± 9.64-3.0 ± 12.73-6.3 ± 7.872.0 ± 16.97
Day 5 - 96 hours post-dose reading 31.0 ± 3.46——-6.0—
Day 8-3.8 ± 8.94-1.4 ± 10.140.1 ± 10.50-3.9 ± 9.540.1 ± 9.01
Day 150.3 ± 11.28-1.6 ± 7.894.4 ± 7.63-2.3 ± 9.95-0.8 ± 10.51
Day 220.4 ± 10.94-1.3 ± 9.561.3 ± 12.44-2.8 ± 7.360.9 ± 9.45
Day 29-1.4 ± 11.183.8 ± 5.97-0.3 ± 10.391.0 ± 11.272.1 ± 11.58
Day 570.3 ± 9.46-3.0 ± 7.142.1 ± 12.29-4.0 ± 8.03-1.2 ± 9.77
Day 850.2 ± 9.99-0.8 ± 7.633.2 ± 13.16-2.8 ± 6.85-0.1 ± 10.75
Day 1130.2 ± 11.49-1.9 ± 5.23-0.9 ± 14.14-4.1 ± 11.20-0.6 ± 12.00
SecondaryChange From Baseline in Mean Arterial Pressure (MAP)
Time frame:
Day 1 (1,2,4,8hrs post-dose readings), Day 2 (24hrs post-dose readings 1,2,3), Day 3 (48hrs post-dose readings 1,2,3), Day 4 (72hrs post-dose readings 1,2,3), Day 5 (96hrs post-dose readings 1,2,3), Day 8, Day 15, Day 22, Day 29, Day 57, Day 85, Day 113
Reported as:
Mean · mmHg
Change From Baseline in Mean Arterial Pressure (MAP)
mmHgPlacebo: Not on SVPlacebo: on SVREGN5381 100 Milligrams (mg): Not on SVREGN5381 100 mg: On SVREGN5381 300 mg: Not on SV
Day 1 - 1 hour post-dose reading-1.0 ± 9.21-6.2 ± 8.45-0.5 ± 8.83-10.0 ± 7.28-1.5 ± 7.77
Day 1 - 2 hours post-dose reading-6.6 ± 8.00-6.9 ± 9.97-11.6 ± 9.94-9.7 ± 11.87-10.3 ± 8.45
Day 1 - 4 hours post-dose reading-4.0 ± 10.13-5.3 ± 7.40-10.3 ± 9.92-11.0 ± 12.13-7.9 ± 6.85
Day 1 - 8 hours post-dose reading-5.8 ± 9.54-8.1 ± 8.83-8.7 ± 10.31-3.2 ± 8.75-9.8 ± 8.38
Day 2 - 24 hours post-dose reading 1-2.4 ± 9.08-5.8 ± 8.03-8.3 ± 10.78-1.9 ± 11.15-4.7 ± 8.20
Day 2 - 24 hours post-dose reading 2-5.2 ± 9.57-6.2 ± 7.56-9.1 ± 12.31-10.6 ± 12.82-4.1 ± 10.69
Day 2 - 24 hours post-dose reading 3-3.2 ± 9.83-5.8 ± 5.29-8.5 ± 13.39-6.8 ± 16.11-4.2 ± 11.31
Day 3 - 48 hours post-dose reading 1-3.6 ± 10.54-6.7 ± 4.80-0.2 ± 11.72-5.6 ± 13.73-0.8 ± 11.05
Day 3 - 48 hours post-dose reading 2-3.4 ± 9.42-8.1 ± 7.52-5.7 ± 11.80-3.8 ± 10.51-2.2 ± 9.74
Day 3 - 48 hours post-dose reading 3-3.2 ± 10.69-8.3 ± 9.12-4.6 ± 10.95-1.5 ± 10.520.2 ± 9.41
Day 4 - 72 hours post-dose reading 1-2.9 ± 12.22-3.3 ± 10.77-2.4 ± 11.442.1 ± 15.612.0 ± 7.79
Day 4 - 72 hours post-dose reading 2-3.5 ± 11.91-1.2 ± 9.96-1.8 ± 11.90-0.4 ± 17.25-1.4 ± 10.22
Day 4 - 72 hours post-dose reading 3-3.0 ± 9.99-5.3 ± 6.49-6.4 ± 9.602.1 ± 16.31-1.8 ± 7.70
Day 5 - 96 hours post-dose reading 1-1.8 ± 11.45-4.9 ± 5.210.3 ± 10.99-0.4 ± 8.141.2 ± 7.59
Day 5 - 96 hours post-dose reading 2-0.7 ± 4.54-3.0 ± 10.42-3.8 ± 10.61-7.6 ± 6.57-0.2 ± 10.14
Day 5 - 96 hours post-dose reading 30.9 ± 4.30——-10.0—
Day 8-4.2 ± 9.37-1.8 ± 8.930.3 ± 10.61-4.8 ± 9.80-0.1 ± 7.38
Day 150.2 ± 11.31-4.8 ± 9.494.6 ± 8.57-1.0 ± 12.470.8 ± 7.87
Day 220.5 ± 11.00-2.7 ± 9.911.7 ± 11.68-0.8 ± 9.542.8 ± 9.97
Day 29-1.5 ± 11.551.6 ± 6.740.6 ± 9.401.2 ± 11.862.3 ± 10.16
Day 570.8 ± 10.48-3.7 ± 8.232.6 ± 11.52-3.7 ± 6.57-0.8 ± 9.22
Day 850.3 ± 9.92-2.1 ± 7.043.3 ± 13.20-3.8 ± 9.140.6 ± 9.97
Day 1130.3 ± 11.52-3.5 ± 4.890.8 ± 14.63-3.6 ± 12.250.4 ± 10.36
SecondaryChange From Baseline in Heart Rate (HR)
Time frame:
Day 1 (1,2,4,8hrs post-dose readings), Day 2 (24hrs post-dose readings 1,2,3), Day 3 (48hrs post-dose readings 1,2,3), Day 4 (72hrs post-dose readings 1,2,3), Day 5 (96hrs post-dose readings 1,2,3), Day 8, Day 15, Day 22, Day 29, Day 57, Day 85, Day 113
Reported as:
Mean · beats per minute
Change From Baseline in Heart Rate (HR)
beats per minutePlacebo: Not on SVPlacebo: on SVREGN5381 100 Milligrams (mg): Not on SVREGN5381 100 mg: On SVREGN5381 300 mg: Not on SV
Day 1 - 1 hour post-dose reading-0.1 ± 8.27-7.1 ± 12.79-0.1 ± 13.423.9 ± 13.09-7.6 ± 12.85
Day 1 - 2 hours post-dose reading3.7 ± 11.39-1.1 ± 8.57-1.4 ± 11.725.6 ± 16.52-3.5 ± 15.25
Day 1 - 4 hours post-dose reading1.2 ± 10.81-1.4 ± 14.51-0.5 ± 10.823.3 ± 14.44-3.0 ± 15.25
Day 1 - 8 hours post-dose reading-0.3 ± 7.53-5.2 ± 11.720.9 ± 15.183.0 ± 10.31-1.5 ± 16.75
Day 2 - 24 hours post-dose reading 1-3.6 ± 7.54-4.1 ± 12.68-6.1 ± 14.650.4 ± 12.45-2.5 ± 20.05
Day 2 - 24 hours post-dose reading 20.4 ± 10.39-4.4 ± 9.32-6.9 ± 12.183.3 ± 20.110.2 ± 17.24
Day 2 - 24 hours post-dose reading 3-0.7 ± 11.20-7.5 ± 12.95-2.9 ± 9.955.6 ± 17.181.2 ± 20.31
Day 3 - 48 hours post-dose reading 1-1.8 ± 11.44-5.3 ± 9.84-4.1 ± 9.782.2 ± 16.20-1.3 ± 15.92
Day 3 - 48 hours post-dose reading 20.1 ± 9.14-3.8 ± 11.81-5.3 ± 12.710.8 ± 17.202.4 ± 17.10
Day 3 - 48 hours post-dose reading 33.0 ± 8.98-6.4 ± 13.45-0.5 ± 10.085.1 ± 11.73-0.4 ± 15.71
Day 4 - 72 hours post-dose reading 1-1.4 ± 8.90-4.2 ± 13.69-6.5 ± 11.9010.0 ± 6.04-3.6 ± 16.80
Day 4 - 72 hours post-dose reading 20.0 ± 9.89-8.2 ± 11.30-4.3 ± 11.247.4 ± 8.803.2 ± 19.36
Day 4 - 72 hours post-dose reading 3-1.5 ± 9.61-3.0 ± 5.81-3.5 ± 10.949.0 ± 13.50-2.0 ± 13.24
Day 5 - 96 hours post-dose reading 1-0.2 ± 9.16-4.4 ± 10.10-4.1 ± 13.843.6 ± 7.11-1.4 ± 19.21
Day 5 - 96 hours post-dose reading 21.2 ± 4.960.9 ± 6.5710.0 ± 11.319.3 ± 7.34-6.0 ± 19.80
Day 5 - 96 hours post-dose reading 33.3 ± 3.06——-14.0—
Day 80.7 ± 10.02-7.8 ± 11.22-3.4 ± 11.694.6 ± 12.150.6 ± 15.83
Day 151.6 ± 13.16-3.1 ± 11.133.5 ± 12.03-0.8 ± 12.040.6 ± 15.06
Day 223.6 ± 10.61-7.5 ± 13.703.1 ± 16.45-2.3 ± 13.39-1.4 ± 14.73
Day 292.8 ± 13.45-2.3 ± 14.302.1 ± 17.75-0.8 ± 16.873.1 ± 15.51
Day 573.1 ± 12.40-2.1 ± 13.82-2.1 ± 16.59-3.9 ± 15.874.1 ± 16.27
Day 852.3 ± 13.491.3 ± 13.51-2.4 ± 11.36-4.1 ± 19.173.5 ± 18.88
Day 1133.4 ± 12.93-4.4 ± 7.670.9 ± 10.30-0.6 ± 11.895.2 ± 22.74
SecondaryConcentration of Total REGN5381 in Serum
Time frame:
Day 0 (pre-dose), Day 0 (post-dose), Days 1, 2, 3, 4, 7, 14, 21, 28, 56, 84, 112
Reported as:
Mean · milligrams per liter (mg/L)
Concentration of Total REGN5381 in Serum
milligrams per liter (mg/L)REGN5381 100 Milligrams (mg): Not on SVREGN5381 100 mg: On SVREGN5381 300 mg: Not on SV
Day 0 (pre-dose)0 ± 00 ± 00 ± 0
Day 0 (post-dose)24.2 ± 5.9028.1 ± 5.7079.1 ± 17.5
Day 118.4 ± 4.1919.4 ± 3.7662.5 ± 13.0
Day 214.4 ± 3.1416.6 ± 2.8852.1 ± 10.6
Day 313.2 ± 2.4614.5 ± 2.8044.1 ± 9.29
Day 412.1 ± 2.3612.8 ± 3.5341.1 ± 10.3
Day 79.08 ± 2.339.30 ± 3.0432.7 ± 7.65
Day 146.12 ± 2.026.29 ± 2.3622.1 ± 5.30
Day 214.15 ± 1.663.91 ± 2.4715.4 ± 5.05
Day 282.59 ± 1.302.28 ± 1.3311.5 ± 4.18
Day 560.0592 ± 0.1120.0441 ± 0.1112.55 ± 2.04
Day 840 ± 00 ± 00.223 ± 0.472
Day 1120 ± 00 ± 00.00513 ± 0.0173
SecondaryNumber of Participants With a Treatment-Emergent Anti-Drug Antibody (ADA) Response to REGN5381
Time frame:
Up to Week 16
Reported as:
Count of participants · Participants
Number of Participants With a Treatment-Emergent Anti-Drug Antibody (ADA) Response to REGN5381
ParticipantsREGN5381 100 Milligrams (mg): Not on SVREGN5381 100 mg: On SVREGN5381 300 mg: Not on SV
Number of Participants With a Treatment-Emergent Anti-Drug Antibody (ADA) Response to REGN5381002
SecondaryMaximum Titer Category of Participants With ADAs to REGN5381
Time frame:
Up to Week 16
Reported as:
Count of participants · Participants
Maximum Titer Category of Participants With ADAs to REGN5381
ParticipantsREGN5381 100 Milligrams (mg): Not on SVREGN5381 100 mg: On SVREGN5381 300 mg: Not on SV
Low001
Moderate001
High000

Adverse events

Collected over From informed consent through end of study (approximately 203 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo: Not on SV1/35 (2.9%)1/35 (2.9%)8/35 (22.9%)
Placebo: on SV0/9 (0%)0/9 (0%)3/9 (33.3%)
REGN5381 100 Milligrams (mg): Not on SV0/19 (0%)1/19 (5.3%)4/19 (21.1%)
REGN5381 100 mg: On SV0/9 (0%)3/9 (33.3%)7/9 (77.8%)
REGN5381 300 mg: Not on SV0/17 (0%)1/17 (5.9%)3/17 (17.6%)
Most frequent serious events
Most frequent serious events
EventPlacebo: Not on SVPlacebo: on SVREGN5381 100 Milligrams (mg): Not on SVREGN5381 100 mg: On SVREGN5381 300 mg: Not on SV
Cardiac failureCardiac disorders1/350/90/191/90/17
Pulmonary oedemaRespiratory, thoracic and mediastinal disorders0/350/90/191/90/17
PneumoniaInfections and infestations0/350/90/191/91/17
Enterocolitis infectiousInfections and infestations0/350/91/190/90/17
Acute myocardial infarctionCardiac disorders1/350/90/190/90/17
PericarditisCardiac disorders1/350/90/190/90/17
Respiratory failureRespiratory, thoracic and mediastinal disorders1/350/90/190/90/17
Most frequent other events
Showing 10 of 31
Most frequent other events
EventPlacebo: Not on SVPlacebo: on SVREGN5381 100 Milligrams (mg): Not on SVREGN5381 100 mg: On SVREGN5381 300 mg: Not on SV
AnaemiaBlood and lymphatic system disorders1/351/90/193/90/17
HyperkalaemiaMetabolism and nutrition disorders1/350/90/193/90/17
Blood creatinine increasedInvestigations1/350/90/192/90/17
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/350/90/192/90/17
Alanine aminotransferase increasedInvestigations2/350/91/191/91/17
Aspartate aminotransferase increasedInvestigations2/350/91/191/91/17
Blood bilirubin increasedInvestigations1/351/90/190/90/17
Blood bilirubin unconjugated increasedInvestigations0/351/90/190/90/17
Blood uric acid increasedInvestigations0/350/90/191/90/17
Lymphocyte count decreasedInvestigations0/350/90/191/90/17

Baseline characteristics

The safety analysis set included all randomized participants who received any study drug.

Age, Continuous
Age, Continuous(years)Placebo: Not on SVPlacebo: on SVREGN5381 100 Milligrams (mg): Not on SVREGN5381 100 mg: On SVREGN5381 300 mg: Not on SVTotal
Mean66.5 ± 8.1861.4 ± 12.8963.7 ± 8.8763.9 ± 9.4564.2 ± 9.9364.7 ± 9.26
Sex: Female, Male
Sex: Female, Male(Participants)Placebo: Not on SVPlacebo: on SVREGN5381 100 Milligrams (mg): Not on SVREGN5381 100 mg: On SVREGN5381 300 mg: Not on SVTotal
Female10183830
Male258116959
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo: Not on SVPlacebo: on SVREGN5381 100 Milligrams (mg): Not on SVREGN5381 100 mg: On SVREGN5381 300 mg: Not on SVTotal
Hispanic or Latino000000
Not Hispanic or Latino3591991789
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo: Not on SVPlacebo: on SVREGN5381 100 Milligrams (mg): Not on SVREGN5381 100 mg: On SVREGN5381 300 mg: Not on SVTotal
American Indian or Alaska Native000000
Asian000000
Native Hawaiian or Other Pacific Islander000000
Black or African American000000
White3591991789
More than one race000000
Unknown or Not Reported000000
Circulating N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP)
Circulating N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP)(picogram per milliliter (pg/mL))Placebo: Not on SVPlacebo: on SVREGN5381 100 Milligrams (mg): Not on SVREGN5381 100 mg: On SVREGN5381 300 mg: Not on SVTotal
Mean1843.3 ± 1200.431988.9 ± 1465.362136.3 ± 2032.701880.6 ± 1068.172193.6 ± 2141.331991.3 ± 1599.05
08

Study locations

44 sites
  • Arensia Exploratory Medicine Clinic
    Phoenix, Arizona 85015, United States
  • Harbor UCLA Medical Center
    Torrance, California 90509, United States
  • Flourish Research - Miami (Kendall) (Formerly Clinical Site Partners)
    Miami, Florida 33186, United States
  • Flourish Research - Orlando (Formerly Clinical Site Partners)
    Winter Park, Florida 32789, United States
  • Grand Hopital de Charleroi
    Gilly, Hainaut 6060, Belgium
  • Anima Research Center
    Alken, Limburg 3570, Belgium
  • Onze Lieve Vrouw Ziekenhuis Aalst
    Aalst, Oost-Vlaanderen 9300, Belgium
  • UZ Leuven
    Leuven, Vlaams Brabant 3000, Belgium
  • Algemeen Ziekenhuis St Jan Brugge Oostende Av
    Bruges, West Flanders 8000, Belgium
  • Algemeen Ziekenhuis Groeninge
    Kortrijk, West Vlaanderen 8500, Belgium
  • AZ Oostende
    Ostend, West Vlaanderen 8400, Belgium
  • Centre Hospitalier Regional de la Citadelle
    Liège, 4000, Belgium
  • MHAT Haskovo
    Haskovo, 6300, Bulgaria
  • University Multiprofile Hospital for Active Treatment Plovdiv
    Plovdiv, 4000, Bulgaria
  • Arensia Exploratory Medicine Clinic at MBAL Sveta Sofia
    Sofia, 1618, Bulgaria
  • Fakultni Nemocnice v Motole
    Prague, Central Bohemian 15006, Czechia
  • University Hospital Brno
    Brno, South Moravian 62500, Czechia
  • Medicus Services s.r.o.
    Brandýs nad Labem-Stará Boleslav, 25001, Czechia
  • Edumed
    Jaroměř, 55101, Czechia
  • Arensia Exploratory Medicine at the Research Institute of Clinical Medicine
    Tbilisi, 0112, Georgia
  • First Cardiology Clinic University of Athens
    Athens, Attica 11527, Greece
  • Athens Naval Hospital
    Athens, Attikh 11521, Greece
  • General University Hospital Attikon
    Chaïdári, 12462, Greece
  • Larissa University Hospital
    Larissa, 41110, Greece
  • Pmsi Republican Clinical Hospital Timofei Mosneaga
    Chisinau, MD-2025, Moldova
  • Wojewodzki Szpital Zespolony - Ludwik Rydygier Provincial Hospital
    Torun, Kuyavian-Pomeranian Voivodeship 87-100, Poland
  • UCK Medical University of Warsaw
    Warsaw, Masovian Voivodeship 02-097, Poland
  • Medical University of Lodz
    Lodz, 90-549, Poland
  • NZOZ Gemini
    Żychlin, 62-571, Poland
  • Clinmedica Research sp zo.o.
    Skierniewice, Łódź Voivodeship 96-100, Poland
  • Arensia Exploratory Medicine Clinic at Monza Bucharest
    Bucharest, 11658, Romania
  • Sc Arensia Exploratory Medicine Srl
    Cluj-Napoca, 400006, Romania
  • Worthwhile Clinical Trials
    Benoni, Gauteng 1500, South Africa
  • Into Research
    Groenkloof, Gauteng 0181, South Africa
  • Dr M I Sarvan,R Moodley & partners
    Durban, KwaZulu-Natal 4321, South Africa
  • Kuils River Hospital
    Kuils River, Western Cape 7580, South Africa
  • Wonju Severance Christian Hospital
    Wŏnju, Gangwon-do 26426, South Korea
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do 13620, South Korea
  • Severance Hospital at Yonsei University College of Medicine
    Seoul, Seodaemun-gu 03722, South Korea
  • Korea University Guro Hospital
    Seoul, 8308, South Korea
  • Virgen de las Montañas Hospital
    Villamartín, Cadiz 11650, Spain
  • Hospital Universitario Virgen de la Arrixaca
    El Palmar, Murcia 30120, Spain
  • Hospital Universitario Virgen Macarena Unidad Coronaria 1 planta
    Seville, 41009, Spain
  • Hospital Arnau de Vilanova
    Valencia, 46015, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2024 to primary completion in Sep 2025, 17 months.

Results were first posted in Nov 2026, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2024
First posted
Feb 1, 2024
StartActual
Apr 11, 2024
Primary completionActual
Sep 17, 2025
CompletionActual
Dec 29, 2025
Results first posted
Nov 19, 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 19, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedFold Change from baselineFrom Baseline in circulatingCirculating N-Terminal proPro-Brain Natriuretic Peptide (NTproBNP)Time frame: Day 8 → Baseline, Day 8
Nov 19, 2026
Documents
Secondary outcomes
8 edited, 1 added, 5 removed
What changed in the outcomes
  • EditedFold Change from baselineFrom Baseline in circulatingCirculating NT-proBNPTime frame: Week 2 → Baseline, Days 15, 22, 29, 57, 85, 113
  • EditedChange from baselineFrom Baseline in Systolic Blood Pressure (SBP)Time frame: Each visit through week 16 → Day 1 (1,2,4,8hrs post-dose readings), Day 2 (24hrs post-dose readings 1,2,3), Day 3 (48hrs post-dose readings 1,2,3), Day 4 (72hrs post-dose readings 1,2,3), Day 5 (96hrs post-dose readings 1,2,3), Day 8, Day 15, Day 22, Day 29, Day 57, Day 85, Day 113
  • EditedChange from baselineFrom Baseline in Diastolic Blood Pressure (DBP)Time frame: Each visit through week 16 → Day 1 (1,2,4,8hrs post-dose readings), Day 2 (24hrs post-dose readings 1,2,3), Day 3 (48hrs post-dose readings 1,2,3), Day 4 (72hrs post-dose readings 1,2,3), Day 5 (96hrs post-dose readings 1,2,3), Day 8, Day 15, Day 22, Day 29, Day 57, Day 85, Day 113
  • EditedChange from baselineFrom Baseline in Mean Arterial Pressure (MAP)Time frame: Each visit through week 16 → Day 1 (1,2,4,8hrs post-dose readings), Day 2 (24hrs post-dose readings 1,2,3), Day 3 (48hrs post-dose readings 1,2,3), Day 4 (72hrs post-dose readings 1,2,3), Day 5 (96hrs post-dose readings 1,2,3), Day 8, Day 15, Day 22, Day 29, Day 57, Day 85, Day 113
  • EditedChange from baselineFrom Baseline in Heart Rate (HR)Time frame: Each visit through week 16 → Day 1 (1,2,4,8hrs post-dose readings), Day 2 (24hrs post-dose readings 1,2,3), Day 3 (48hrs post-dose readings 1,2,3), Day 4 (72hrs post-dose readings 1,2,3), Day 5 (96hrs post-dose readings 1,2,3), Day 8, Day 15, Day 22, Day 29, Day 57, Day 85, Day 113
  • EditedConcentrationsConcentration of Total REGN5381 in serumSerumTime frame: Through week 16 → Day 0 (pre-dose), Day 0 (post-dose), Days 1, 2, 3, 4, 7, 14, 21, 28, 56, 84, 112
  • EditedIncidenceNumber of Participants With a Treatment-Emergent Anti-Drug AntibodiesAntibody (ADAsADA) Response to REGN5381Time frame: Through week 16 → Up to Week 16
  • EditedMagnitudeMaximum Titer Category of Participants With ADAs to REGN5381Time frame: Through week 16 → Up to Week 16
  • AddedNumber of Participants With at Least One Treatment Emergent Adverse Event (TEAE) by SeverityTime frame: Up to Week 16
  • RemovedOccurrence of Treatment Emergent Adverse Events (TEAEs)Time frame: Through week 16
  • RemovedSeverity of TEAEsTime frame: Through week 16
  • RemovedChange from baseline in circulating NT-proBNPTime frame: Week 3
  • RemovedChange from baseline in circulating NT-proBNPTime frame: Week 4
  • RemovedChange from baseline in circulating NT-proBNPTime frame: Up to week 16
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedFold Change from baselineFrom Baseline in circulatingCirculating N-Terminal proPro-Brain Natriuretic Peptide (NTproBNP)Time frame: Day 8 → Baseline, Day 8
    Secondary outcomes 8 edited, 1 added, 5 removed
    What changed in the outcomes
    • EditedFold Change from baselineFrom Baseline in circulatingCirculating NT-proBNPTime frame: Week 2 → Baseline, Days 15, 22, 29, 57, 85, 113
    • EditedChange from baselineFrom Baseline in Systolic Blood Pressure (SBP)Time frame: Each visit through week 16 → Day 1 (1,2,4,8hrs post-dose readings), Day 2 (24hrs post-dose readings 1,2,3), Day 3 (48hrs post-dose readings 1,2,3), Day 4 (72hrs post-dose readings 1,2,3), Day 5 (96hrs post-dose readings 1,2,3), Day 8, Day 15, Day 22, Day 29, Day 57, Day 85, Day 113
    • EditedChange from baselineFrom Baseline in Diastolic Blood Pressure (DBP)Time frame: Each visit through week 16 → Day 1 (1,2,4,8hrs post-dose readings), Day 2 (24hrs post-dose readings 1,2,3), Day 3 (48hrs post-dose readings 1,2,3), Day 4 (72hrs post-dose readings 1,2,3), Day 5 (96hrs post-dose readings 1,2,3), Day 8, Day 15, Day 22, Day 29, Day 57, Day 85, Day 113
    • EditedChange from baselineFrom Baseline in Mean Arterial Pressure (MAP)Time frame: Each visit through week 16 → Day 1 (1,2,4,8hrs post-dose readings), Day 2 (24hrs post-dose readings 1,2,3), Day 3 (48hrs post-dose readings 1,2,3), Day 4 (72hrs post-dose readings 1,2,3), Day 5 (96hrs post-dose readings 1,2,3), Day 8, Day 15, Day 22, Day 29, Day 57, Day 85, Day 113
    • EditedChange from baselineFrom Baseline in Heart Rate (HR)Time frame: Each visit through week 16 → Day 1 (1,2,4,8hrs post-dose readings), Day 2 (24hrs post-dose readings 1,2,3), Day 3 (48hrs post-dose readings 1,2,3), Day 4 (72hrs post-dose readings 1,2,3), Day 5 (96hrs post-dose readings 1,2,3), Day 8, Day 15, Day 22, Day 29, Day 57, Day 85, Day 113
    • EditedConcentrationsConcentration of Total REGN5381 in serumSerumTime frame: Through week 16 → Day 0 (pre-dose), Day 0 (post-dose), Days 1, 2, 3, 4, 7, 14, 21, 28, 56, 84, 112
    • EditedIncidenceNumber of Participants With a Treatment-Emergent Anti-Drug AntibodiesAntibody (ADAsADA) Response to REGN5381Time frame: Through week 16 → Up to Week 16
    • EditedMagnitudeMaximum Titer Category of Participants With ADAs to REGN5381Time frame: Through week 16 → Up to Week 16
    • AddedNumber of Participants With at Least One Treatment Emergent Adverse Event (TEAE) by SeverityTime frame: Up to Week 16
    • RemovedOccurrence of Treatment Emergent Adverse Events (TEAEs)Time frame: Through week 16
    • RemovedSeverity of TEAEsTime frame: Through week 16
    • RemovedChange from baseline in circulating NT-proBNPTime frame: Week 3
    • RemovedChange from baseline in circulating NT-proBNPTime frame: Week 4
    • RemovedChange from baseline in circulating NT-proBNPTime frame: Up to week 16
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06237309
Responsible party
Sponsor
First posted
Feb 1, 2024
Start date
Apr 11, 2024
Primary completion
Sep 17, 2025
Completion
Dec 29, 2025
Results posted
Nov 19, 2026
Last update
Nov 19, 2026

Study contacts

Clinical Trials Administrator
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vixticibart

Start the discussion